Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 20,013 Shares of Stock

Key Points

• Invivyd insider Julie Green sold 20,013 shares on August 18 for $0.65 each, totaling approximately $13,008, which marked a 20.22% reduction in her holdings.
• The company's stock traded down by 1.7% to $0.5710, with a market capitalization of $68.60 million and a P/E ratio of -0.62 following disappointing earnings.
• Analysts have mixed sentiments on Invivyd, with a consensus buy rating and a **revised price target** of $3.85 after D. Boral Capital lowered its estimate from $9.00 to $3.00.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Julie Green sold 20,013 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $0.65, for a total value of $13,008.45. Following the transaction, the insider owned 78,987 shares in the company, valued at approximately $51,341.55. This represents a 20.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Julie Green also recently made the following trade(s):

• On Tuesday, August 19th, Julie Green sold 29,643 shares of Invivyd stock. The stock was sold at an average price of $0.57, for a total value of $16,896.51.

Invivyd Trading Down 1.7%

NASDAQ IVVD traded down $0.0101 on Tuesday, hitting $0.5710. The company's stock had a trading volume of 1,690,635 shares, compared to its average volume of 850,421. Invivyd, Inc. has a 52-week low of $0.3546 and a 52-week high of $2.74. The company's 50-day simple moving average is $0.75 and its 200 day simple moving average is $0.84. The firm has a market cap of $68.60 million, a P/E ratio of -0.62 and a beta of 0.51.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The business had revenue of $11.79 million during the quarter, compared to analysts' expectations of $23.16 million. On average, research analysts forecast that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Invivyd

Several large investors have recently made changes to their positions in IVVD. JPMorgan Chase & Co. lifted its holdings in shares of Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock valued at $114,000 after purchasing an additional 222,375 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Invivyd during the fourth quarter valued at approximately $74,000. Barclays PLC lifted its holdings in shares of Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after purchasing an additional 9,207 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after purchasing an additional 87,358 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Invivyd by 35.2% during the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock valued at $385,000 after purchasing an additional 227,463 shares during the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IVVD has been the subject of several research analyst reports. D. Boral Capital dropped their price objective on Invivyd from $9.00 to $3.00 and set a "buy" rating for the company in a report on Friday. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Invivyd in a report on Thursday, June 26th. One research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $3.85.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.